Diagnostic value of HE4+ circulating tumor cells in patients with suspicious ovarian cancer

Yan-xiu Guo; Kuang Hong Neoh; Xiao-hong Chang; Yukun Sun; Hong-yan Cheng; Xue Ye; Rui-qiong Ma; Ray P.S. Han; Heng Cui

doi:10.18632/oncotarget.23943

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Diagnostic value of HE4+ circulating tumor cells in patients with suspicious ovarian cancer

Yan-xiu Guo, Kuang Hong Neoh, Xiao-hong Chang, Yukun Sun, Hong-yan Cheng, Xue Ye, Rui-qiong Ma, Ray P.S. Han _ and Heng Cui

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2018; 9:7522-7533. https://doi.org/10.18632/oncotarget.23943

Metrics: PDF 2186 views | HTML 3067 views | ?

Abstract

Yan-Xiu Guo1,*, Kuang Hong Neoh2,*, Xiao-Hong Chang1, Yukun Sun2, Hong-Yan Cheng1, Xue Ye1, Rui-Qiong Ma1, Ray P.S. Han2 and Heng Cui1

1Center of Gynecologic Oncology, Peking University People’s Hospital, Beijing, China

2College of Engineering, Peking University, Beijing, China

*These authors contributed equally to this work

Correspondence to:

Ray P.S. Han, email: [email protected]

Heng Cui, email: [email protected]

Keywords: circulating tumor cells; microfluidic isolation; HE4; ovarian cancer; diagnosis

Received: July 21, 2017 Accepted: December 27, 2017 Published: January 04, 2018

ABSTRACT

Lacking a satisfactory screening test, ovarian cancer is frequently diagnosed at a late stage, leading to poor patient outcomes. This study investigated the diagnostic value of circulating tumor cells (CTCs) in peripheral blood from patients with suspected ovarian tumors. Sixty-one women suspected of having an ovarian mass were prospectively enrolled in this study. CTCs were identified and counted using microfluidic isolation and immunofluorescent staining of CD45, HE4, and epithelial and mesenchymal (E&M) markers (epithelial cell adhesion molecule, cytokeratins, and vimentin). Thirty (49%) of the patients were diagnosed with ovarian cancer. DAPI+/E&M+/CD45-/HE4+ CTC counts were higher in these patients than in patients with benign tumors (p = 0.016). The receiver operating characteristic (ROC) curve showed that the sensitivity of CTCs was 73.3%, which was superior to that of CA125 (56.7%). In patients with elevated CA125 levels (≥35 U/ml), CTC counts still showed good specificity (86.7%). Our findings suggest the DAPI+/E&M+/CD45-/HE4+ CTC count is a useful diagnostic indicator in patients with suspected ovarian cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23943

Publication Alerts

Research Papers:

Diagnostic value of HE4+ circulating tumor cells in patients with suspicious ovarian cancer

Abstract